WallStreetZen

NYSE: NVS
Novartis Ag Stock Forecast, Predictions & Price Target

Analyst price target for NVS

Based on 3 analysts offering 12 month price targets for Novartis Ag.
Min Forecast
$109.00+12.51%
Avg Forecast
$110.50+14.06%
Max Forecast
$112.50+16.12%

Should I buy or sell NVS stock?

Strong Buy
Strong Buy
7 analysts 77.78%
Buy
0 analysts 0%
Hold
1 analysts 11.11%
Sell
0 analysts 0%
Strong Sell
1 analysts 11.11%

Forecast return on equity

Is NVS forecast to generate an efficient return?
Company
32.79%
Industry
75.15%
Market
62.3%
NVS's Return on Equity is forecast to be high in 4 years (32.79%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NVS forecast to generate an efficient return on assets?
Company
15.37%
Industry
16.93%
Market
19.84%
NVS is forecast to generate lower Return on Assets (15.37%) than the US Drug Manufacturers - General industry average (16.93%)
Forecast

NVS earnings per share forecast

What is NVS's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$6.52+27.27%
Avg 2 year Forecast
$7.08+38.18%
Avg 3 year Forecast
$7.51+46.68%
NVS's earnings are forecast to grow at a rate of 13.82% per year, which is not exceptional
Forecast

NVS revenue forecast

What is NVS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$53.6B+10.1%
Avg 2 year Forecast
$55.8B+14.72%
Avg 3 year Forecast
$58.7B+20.62%
NVS's revenue is forecast to grow at a rate of 6.34% per year, which is not exceptional
Forecast

NVS earnings growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
13.82%
Industry
25.09%
Market
20.63%
NVS's earnings are forecast to grow slower (13.82% per year) than the US Drug Manufacturers - General industry average (25.09%)
Forecast
NVS's earnings are forecast to grow slower (13.82% per year) than the US market average (20.63%)
Forecast
NVS's earnings are forecast to grow faster (13.82% per year) than the risk-free savings rate (1.1%)
Forecast

NVS revenue growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
6.34%
Industry
6.43%
Market
14.47%
NVS's revenues are forecast to grow slower (6.34% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
NVS's revenues are forecast to grow slower (6.34% per year) than the US market average (14.47%)
Forecast

Novartis Ag Stock Forecast FAQ

Is Novartis Ag Stock a good buy in 2019, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NYSE: NVS) stock is to Strong Buy NVS stock.

Out of 9 analysts, 7 (77.78%) are recommending NVS as a Strong Buy, 0 (0%) are recommending NVS as a Buy, 1 (11.11%) are recommending NVS as a Hold, 0 (0%) are recommending NVS as a Sell, and 1 (11.11%) are recommending NVS as a Strong Sell.

What is NVS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year NVS price target, the average NVS price target is $110.50, with the highest NVS stock price forecast at $112.50 and the lowest NVS stock price forecast at $109.00.

On average, Wall Street analysts predict that Novartis Ag's share price could reach $110.50 by Jan 20, 2022. The average Novartis Ag stock price prediction forecasts a potential upside of 14.06% from the current NVS share price of $96.88.

What is NVS's earnings growth forecast for 2021-2023?

(NYSE: NVS) Novartis Ag's forecast annual earnings growth rate of 13.82% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 25.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.63%.

Novartis Ag's earnings in 2019 is $11,732,000,000.On average, 5 Wall Street analysts forecast NVS's earnings for 2021 to be $15,059,593,031, with the lowest NVS earnings forecast at $14,791,497,146, and the highest NVS earnings forecast at $15,230,619,717. On average, 2 Wall Street analysts forecast NVS's earnings for 2022 to be $16,351,537,860, with the lowest NVS earnings forecast at $16,131,976,574, and the highest NVS earnings forecast at $16,571,099,146.

In 2023, NVS is forecast to generate $17,356,897,432 in earnings, with the lowest earnings forecast at $17,356,897,432 and the highest earnings forecast at $17,356,897,432.

What is NVS's revenue growth forecast for 2021-2023?

(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 6.34% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.

Novartis Ag's revenue in 2019 is $48,677,000,000.On average, 2 Wall Street analysts forecast NVS's revenue for 2021 to be $123,861,420,141,111, with the lowest NVS revenue forecast at $122,843,314,459,065, and the highest NVS revenue forecast at $124,879,525,823,157. On average, 2 Wall Street analysts forecast NVS's revenue for 2022 to be $129,063,578,131,361, with the lowest NVS revenue forecast at $126,658,480,695,487, and the highest NVS revenue forecast at $131,468,675,567,236.

In 2023, NVS is forecast to generate $135,702,741,625,164 in revenue, with the lowest revenue forecast at $135,702,741,625,164 and the highest revenue forecast at $135,702,741,625,164.

What is NVS's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: NVS) Novartis Ag's current Earnings Per Share (EPS) is $5.12. On average, analysts forecast that NVS's EPS will be $6.52 for 2021, with the lowest EPS forecast at $6.40, and the highest EPS forecast at $6.59. On average, analysts forecast that NVS's EPS will be $7.08 for 2022, with the lowest EPS forecast at $6.98, and the highest EPS forecast at $7.17. In 2023, NVS's EPS is forecast to hit $7.51 (min: $7.51, max: $7.51).

What is NVS's forecast return on equity (ROE) for 2021-2024?

(NYSE: NVS) forecast ROE is 32.79%, which is considered strong.

What is NVS's forecast return on assets (ROA) for 2021-2024?

(NYSE: NVS) forecast ROA is 15.37%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.93%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics